ADENOSINE A2A RECEPTOR ANTAGONISM AFFORDS INTEGRATED BENEFITSNEUROLOGICAL SYMPTOMS NEUROFIBROMATOSIS TYPE I

$0FY2018Defense Health AgencyDOD

Centro De NeurociêNcias E Biologia Celular

Investigators